Navigation Links
Dialysis patients' anxiety and depression linked to physical impairments
Date:5/28/2014

LOS ANGELES (May 28, 2014) With the rate of chronic kidney disease on the rise among older Americans, researchers seeking to improve patients' quality of life studied a group of adults undergoing hemodialysis and found their higher rates of depression and anxiety could be associated with their impaired physical exercise capability and reduced daily physical activity, according a new study published online by the Journal of Renal Nutrition.

The researchers studied 72 relatively healthy maintenance hemodialysis patients and compared them to 39 healthy adults who were not on dialysis. They found significantly higher rates of anxiety and depression among the dialysis patients, than among the adults who were not on dialysis. They also found the dialysis patients suffering from depression and anxiety had the greatest impairments in physical exercise performance and daily physical activity.

"Adults undergoing dialysis often have less daily physical activities than other adults, but little was known about what, if any, effect this reduced activity had on their mental state," said Joel D. Kopple, MD, Los Angeles Biomedical Research Institute (LA BioMed) lead researcher. "Our study found an association between reduced daily physical activities and depression and anxiety. Also, the capacity to perform physical exercise was diminished in these patients. These findings provide a strong rationale for studying whether increased daily physical activity can reduce depression and anxiety among adults undergoing dialysis."

Each person enrolled in the study took walks, climbed stairs and engaged in other physical activities so that researchers could determine their physical abilities. The researchers gauged their depression and anxiety using standardized tests and found 43% of the dialysis patients had anxiety and 33% suffered from depression. In comparison, only 2.5% of the adults who were not on dialysis had anxiety and only 5% of them suffered from depression.

Approximately one in 10 Americans has some form of chronic kidney disease, and the incidence of chronic kidney disease among people ages 65 and older more than doubled between 2000 and 2008, according to the Centers for Disease Control and Prevention.

Hemodialysis is a life-preserving treatment for hundreds of thousands of Americans with kidney failure. It is a medical procedure to remove fluid and waste products from the blood and to correct electrolyte imbalances. This is accomplished using a machine and a dialyzer, which is sometimes described as an "artificial kidney."

"Research is important to improve the quality of life of patients undergoing dialysis," said Dr. Kopple. "With the growing population of people undergoing dialysis, this research is growing in importance."


'/>"/>

Contact: Laura Mecoy
Lmecoy@labiomed.org
310-546-5860
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed)
Source:Eurekalert  

Related medicine news :

1. Image-guided peritoneal dialysis catheter placement significantly reduces complications
2. Bernstein Liebhard LLP Publishes New GranuFlo Lawsuit Website for Individuals Allegedly Affected by 2012 Dialysis Drug Recall
3. More Than 430 Cases Now Filed in Federal GranuFlo Lawsuit Litigation, Bernstein Liebhard LLP Continues to Investigate Dialysis Claims
4. InventHelp® Client Invention, MC DONALD, Secures a Dialysis Tube to a Toilet (FLA-2367)
5. Bernstein Liebhard LLP Launches New GranuFlo Lawsuit Website for Individuals Allegedly Injured by Recalled Dialysis Medications
6. Hemodialysis Industry for Global and China 2013 Analysis in New Research Report at ChinaMarketResearchReports.com
7. GranuFlo Lawsuit News: Bernstein Liebhard LLP Notes Issuance of New Order in Federal Dialysis Lawsuits Against Fresenius Medical Care
8. Fresenius Leads with nearly 50% of the Growing U.S. Dialysis Devices and Concentrates Market, Reports iData Research
9. Hemodialysis & Peritoneal Dialysis Market 2018 Forecasts in New Research Report at RnRMarketResearch.com
10. Investigational drug effective in treating iron deficiency in kidney disease patients on dialysis
11. Investigational Drug Effective in Treating Iron Deficiency in Chronic Kidney Disease Patients on Dialysis: Study
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Dialysis patients' anxiety and depression  linked to physical impairments
(Date:2/6/2016)... IL (PRWEB) , ... February 06, 2016 , ... ... recovery phases of eating disorder treatment helps to reduce the frequency and level ... of the Recovery Phase: Re-Establishing Healthy Identity and Purpose,” will explore the critical ...
(Date:2/5/2016)... ... February 05, 2016 , ... Successful recruitment ... new clinical and scientific initiatives have all marked the last 12 months at ... and CEO of the nation’s oldest cancer center, Candace S. Johnson, PhD, outlined ...
(Date:2/5/2016)... ... February 05, 2016 , ... Freed-Hardeman University President Joe ... signed a joint enrollment and degree completion agreement. The agreement, which begins ... degrees at FHU|Dickson. , The agreement allows students to be jointly admitted ...
(Date:2/5/2016)... ... ... The American public tends to feel uncomfortable about drinking recycled waste water ... well water. The recent experience with lead contaminated water in Flint, Michigan, according to ... increasing public acceptance of recycled waste water as drinking water. , The Flint ...
(Date:2/5/2016)... , ... February 05, 2016 , ... At its annual ... Patrick McDermott as Chairman of the National Board of Directors. Mr. McDermott succeeds former ... the Board,” stated Leslie A. Chambers , APDA President and CEO. “Pat has ...
Breaking Medicine News(10 mins):
(Date:2/4/2016)... , Feb. 4, 2016 Summary Breast ... cancer and the most common cancer in women worldwide, ... disease exceedingly prevalent. The number of women diagnosed with ... but the number of deaths has declined due to ... treatment has been revolutionized in the past four decades, ...
(Date:2/4/2016)... Feb. 4, 2016 Mettler-Toledo International Inc. (NYSE: ... 2015.  Provided below are the highlights: , ... compared with the prior year.  Reported sales decreased 3% ... quarter. , Net earnings per diluted share as ... prior- year period.  Adjusted EPS was $4.65, an increase ...
(Date:2/4/2016)... 2016  Blueprint Medicines Corporation (NASDAQ: BPMC ... selective investigational kinase medicines for patients with genomically ... board of directors of Lonnel Coats , ... of industry-related experience. Jeffrey Albers ... strong strategic experience developing and commercializing numerous oncology ...
Breaking Medicine Technology: